Acute promyelocytic leukemia (APL) is a unique subtype of acute myeloid leukemia that is characterized by distinct clinical, morphological, cytogenetic, and molecular abnormalities. It is associated with a striking risk of early hemorrhagic death due to disseminated intravascular coagulation and hyperfibrinolysis. The prognosis of APL has improved dramatically following the introduction of all-trans retinoic acid (ATRA) and its combination with anthracycline-based chemotherapy during induction and consolidation. Patients with high-risk APL, defined by a white cell count 910×10 9 /L at diagnosis, also appear to benefit from the addition of intermediate-or high-dose cytarabine during consolidation. Arsenic trioxide (ATO) has proved to be even more effective than ATRA as a single agent, and is now routinely used for the treatment of the 20%-30% of patients who manifest disease relapse after initial treatment with ATRA and chemotherapy. ATO has a toxicity profile that differs considerably from that of both ATRA and cytotoxic chemotherapy, and accordingly presents its own specific challenges during treatment. Optimizing a strategy for the incorporation of ATO into initial therapy is currently the focus of several cooperative group trials, with an emphasis on minimizing or even eradicating the use of chemotherapy. ATRA plus ATO without chemotherapy appears to be adequate during induction and consolidation for patients with standard-risk APL, but triple therapy that includes limited anthracycline or gemtuzumab ozogamicin (GO) during induction is required for high-risk APL. Uncertainty still exists regarding the minimum amount of chemotherapy and number of consolidation cycles necessary, the optimal scheduling of ATO, and the potential utility of oral ATO administration. Although prolonged oral maintenance therapy is usually included in most current APL treatment protocols, its value remains controversial, and the superior anti-leukemic efficacy of ATO-based therapy may facilitate its elimination in the future.
Introduction
Acute promyelocytic leukemia [1, 2] (APL) was first recognized as a specific entity in 1957 [3] on the basis of a preponderance of promyelocytes in the marrow, a propensity for bleeding, and a rapidly fatal course. It accounts for 10%-15% of de novo acute myeloid leukemia (AML) cases, and can also be seen as a form of secondary AML, usually following topoisomerase II inhibitor therapy [4] [5] [6] . Unfortunately, the hemorrhagic diathesis of APL is exacerbated by chemotherapy, and an early death rate exceeding 20% hindered progress until the introduction of all-trans retinoic acid (ATRA) in 1988 [7] . Subsequently, highly significant improvements in outcomes have been achieved following the combination of ATRA with either anthracycline-based chemotherapy or with arsenic trioxide (As 2 O 3; ATO).
NuMA [14] , STAT5b [15] , PRKAR1A [16] , FIP1L1 [17] , or BCOR [18] . Although published clinical experience with these variant forms of APL is limited, they appear to exhibit differential responsiveness to ATRA and ATO [19] .
Disruption of normal myeloid differentiation by chimeric PML-RARA proteins is associated with maturation arrest at the promyelocyte stage. Murine models of APL indicate PML-RARA is necessary, but not sufficient, for leukemogenesis and additional genetic abnormalities are required to provide a proliferative signal [20, 21] . In 40%-50% of patients with APL that signal appears to be provided by constitutive activation of FLT3 [22, 23] resulting from either an internal tandem duplication in the juxta-membrane or kinase-I domains, or point mutation in the kinase-II domain. The origin of the putative proliferative signal in the remainder has not yet been identified.
Clinical features
The median age at diagnosis is approximately 45 years, and APL affects both sexes equally [24] . In the US, the age-adjusted annual incidence is 0.23 per 100,000 of population. For unexplained reasons, the incidence of APL is substantially higher in Latinos [25] , and the body mass index of patients with APL is significantly greater than that of patients with other subtypes of AML [26] . Bleeding dominates the initial presentation, and initiation of ATRA combined with aggressive platelet and plasma support to correct the hemostatic defects should be undertaken as soon as the diagnosis is suspected. Pancytopenia is usually present, with a median white cell count (WCC) around 2.5 × 10 9 /L. In approximately 80% of patients the promyelocytes are hypergranular, often with numerous Auer rods (classical APL), and this subtype was designated M3 in the French-American-British classification of AML. The remaining patients have the variant microgranular form (M3v), with bilobed nuclei and few or no Auer rods. The hemostatic defect that is almost inevitably present at diagnosis is multifactorial [27•] , with contributions from primary fibrinolysis and fibrinogenolysis, procoagulant activation with disseminated intravascular coagulation (DIC), secondary fibrinolysis, and endothelial/monocyte perturbation by inflammatory cytokines. In addition, thrombocytopenia may be severe due to both DIC and leukemia-associated marrow failure. PML-RARA fusion genes can be detected in bone marrow preparations by fluorescence in situ hybridization with PML-RARA fusion or RARA break-apart probes, and PML-RARA transcripts are readily identified in reverse transcriptase polymerase chain reaction (RT-PCR) assays. The PML protein normally resides in large macromolecular intra-nuclear structures known as nuclear bodies, and these are disrupted in APL [28] ; this phenomenon can be exploited as a rapid diagnostic test by the use of immuno-fluorescence with anti-PML antibodies [29] .
Features that have been associated with an inferior prognosis include a higher WCC, lower platelet count, older age, FLT3 mutation, CD56 expression, and longer time to achieve remission. The Sanz risk classification [30] , based on cut-points for WCC (10×10 9 /L) and platelet count (40×10 9 /L) is widely used to stratify patients.
Treatment Current treatment options
Prior to the use of ATRA, APL was regarded as the AML subtype with the poorest prognosis, primarily due to early deaths as a result of intracerebral or intrapulmonary hemorrhage. Such bleeding was aggravated when cytotoxic chemotherapy was commenced. Since ATRA relieves the differentiation block and rapidly reverses the hemostatic abnormalities, the risk of early hemorrhagic death is now G10%, provided optimal hemostatic support is also delivered. Notably, the reduction in early deaths has been striking for patients treated in the clinical trial setting, but in population-based studies, the early death rate remains disturbingly high [24] . Unfortunately ATRA is also associated with a potentially fatal capillary-leak syndrome, originally termed "retinoic acid syndrome" [31] , and now known as APL "differentiation syndrome" (DS). DS is characterized by fever, pulmonary infiltrates, and hypoxia, pleural and pericardial effusions, weight gain, renal failure and hypotension.
Following the initial report from Shanghai of the efficacy of ATRA [7] , in which all 24 patients treated achieved complete remission (CR), the necessity for its inclusion as part of initial therapy was unequivocally established in the European APL91 trial [32] that compared ATRA plus chemotherapy (daunorubicin and cytarabine) with chemotherapy alone. The study was terminated when an interim analysis demonstrated that the ATRA-containing arm was associated with superior event-free survival (79% vs 50%) and a significantly lower relapse rate (19% vs 40%) at 12 months. In the group's subsequent trial (APL93), treatment with concurrent ATRA and chemotherapy was associated with significantly fewer relapses than sequential ATRA and chemotherapy [33] .
Precisely which chemotherapeutic agents are most active in APL has long been controversial. Retrospective multivariate analysis of data from Southwest Oncology Group AML trials [34] suggested that outcomes were improved with increased cumulative doses of daunorubicin, whereas cytarabine dose, and inclusion of other agents were not significantly associated with outcome. Data from the GIMEMA group also indicated that another anthracycline, idarubicin, was particularly active in APL [35] . They then combined ATRA with idarubicin in the AIDA 0493 proto-col [36] , and this combination has proven highly effective, especially when followed by consolidation that also utilizes anthracycline-based chemotherapy [37] .
Although early studies suggested cytarabine was of no benefit in APL, recent studies [38, 39•, 40] which utilize intermediate-or high-dose cytarabine during consolidation have demonstrated improved outcomes, particularly for patients with high-risk disease. However, death in remission due to chemotherapy-related toxicity remains an area of concern with such an approach. While ATO is regarded as the treatment of choice for patients whose disease relapses after ATRA and chemotherapy (discussed below), its inclusion in the initial treatment of APL has occurred more slowly. A small randomized study [41] showed that time to CR and the depth of molecular response with the combination of ATRA plus ATO during induction was superior to either agent used alone, and 4 more recent studies from the MD Anderson Cancer Center [46] . The first treatment of a patient with APL using a crude ATO preparation (Ailing No. 1), was in 1973, and 73 cases were published in 1981 [47] , several years before the benefits of ATRA were appreciated. A further 32 cases were reported in the Chinese literature in 1992 [48] , with 66% achieving CR. Investigators from Shanghai and Harbin subsequently showed that ATO could induce both differentiation and apoptosis of APL cells in a dose-dependent manner [49] , and it is now recognized that ATO has potent and relatively selective activity against APL-initiating cells via its ability to induce PML-RARA fusion protein degradation [50, 51] .
Treatment of relapsed APL with ATO
& Despite its long history in traditional Chinese medicine, it was not until the latter part of the 18th century that therapeutic arsenic appeared in the Western medical literature. It was used for the treatment of agues, malaria, syphilis, skin conditions, and parasitic infestations, and was particularly popular in veterinary medicine. In 1865, Lissauer used potassium arsenite (Fowler's solution) to treat a woman with chronic myeloid leukemia (CML), and in 1931 Forkner and Scott reported substantial improvements in blood counts and reduction of splenomegaly in 9 of 10 patients with CML [52] . Another 66 years passed before the benefits of ATO for the treatment of relapsed APL were described in Western literature [53] . Fourteen of 15 patients with APL that had relapsed after ATRA and chemotherapy achieved CR with intravenous (IV) ATO, either alone, or with ATRA or low dose chemotherapy. ATO was rapidly eliminated from plasma, but reversibly accumulated in hair and nails, where its concentration declined after treatment cessation. & This remarkable success with ATO was replicated in a pilot study in New York [54] , in which 11 of 12 patients with heavily pre-treated relapsed APL achieved CR, including 8 who achieved molecular remission. Evidence of both differentiation (progressive reduction in CD33 and increase in CD11b expression) and apoptosis (caspase activation) were demonstrated, consistent with the previously reported in vitro data. & This pilot study was followed by a US Multicenter study [55] of ATO in 40 patients with relapsed APL who were treated for up to 60 days, followed by 1 consolidation cycle of up to 35 days, with further maintenance cycles permitted. The CR rate was 85%, and molecular CR was attained in 86% following consolidation. At 18 months, overall survival (OS) and relapse-free survival (RFS) were 66% and 56% respectively, although patients were not censored at the time of subsequent transplants (8 allogeneic and 3 autologous). Toxicities included gastrointestinal effects (nausea, vomiting, and diarrhea), hyperleukocytosis, and APL DS, QTc prolongation 9500 msec, peripheral neuropathy, and hepatic dysfunction. Despite the small sample size, these data secured regulatory approval for ATO in the treatment of relapsed/refractory APL after ATRA/anthracycline in the US, after retinoid/chemotherapy in Europe, and for the treatment of relapsed APL in Australia. & Other, mostly supportive, data from nearly 200 patients for the use of ATO in relapsed APL have been published from many centers, including reports from Shanghai (n047) [56] , Melbourne (n02) [57] , Hong Kong (n029) [58, 59] , Florence (n07) [60] , Paris (n020) [61] , Hamamatsu (n034) [62] , Houston (n020) [63, 64] , Rome (n0 11) [65] , and multiple French institutions (n025) [66] . The dose of ATO used was either 10 mg/day or 0.15 mg/kg/day. The Shanghai group also described apparently comparable results in 20 patients treated with half-dose ATO (0.08 mg/kg/day), and observed a lower incidence of facial edema, gastrointestinal, and cardiac toxicity [67] . & The duration of ATO therapy, the addition of other agents such as ATRA and chemotherapy or GO, and the contribution of subsequent autologous or allogeneic stem-cell transplantation to the favorable outcomes achieved with ATO in the relapse setting have all been highly variable.
Of particular interest is a study from Vellore [68•] in patients with relapsed APL who underwent salvage with an ATO-based regimen. Thirtythree of 37 patients achieved molecular remission, and received consolidation with further ATO ± ATRA, or an autologous stem-cell transplant after busulfan/cyclophosphamide conditioning. Although not a randomized study, a significantly lower EFS (34.5%) was observed with ATO treatment compared with autologous transplantation (83.3%; P0 0.001). These data contrast with an earlier report from Hong Kong [59] suggesting better OS when patients with relapsed APL underwent salvage with ATO and idarubicin, compared with ATRA/chemotherapy ± allogeneic bone marrow transplantation, despite a high relapse rate in the ATO cohort (38%). Accordingly, apart from the use of ATO as the cornerstone for the treatment of relapsed APL after ATRA and chemotherapy, there is no clear consensus on optimal management after achievement of a second remission [69] .
ATO as initial therapy for APL
& The impressive results obtained with ATO in the treatment of relapsed APL clearly suggested a potential role in initial therapy, either alone, or in combination with other agents. However, enthusiasm was muted when 7 cases of hepatic toxicity, including 2 fatalities, were observed among 11 patients with newly diagnosed APL treated with ATO [56] . The authors argued that ATO should therefore not be used as initial therapy, but a subsequent larger study from Shanghai provided more reassuring efficacy and toxicity data. Shen et al. compared single agent ATRA, single agent ATO, and combined ATRA/ATO in a randomized study of 61 patients. The CR rates were similar in all 3 arms (90%-95%), but statistically significant differences in the median time to CR were observed (ATRA 40.5, ATO 31, ATRA/ATO 25.5 days). These results were supplemented by quantitative PML-RARA RT-PCR as a measure of residual disease, with the lowest levels observed in the combination group following both induction and consolidation, reinforcing the impression that ATRA and ATO act synergistically. Even more importantly, no relapses were observed in the group that received combination therapy, whereas 2 relapses were seen with ATO, and 5 with ATRA. & The median follow-up was only 18 months at initial publication, but updated results [70] with combination ATRA/ATO in 85 patients and a median follow-up of 5.8 years described a 94% CR rate, with 5-year probabilities of RFS and OS an impressive 94.8% and 91.7%, respectively. Although ATRA and ATO were used for remission induction and maintenance, it is noteworthy that remissions were extensively consolidated with multiple cycles of chemotherapy, incorporating daunorubicin, conventional-and intermediate-dose cytarabine, and homoharringtonine (omacetaxine mepesuccinate). & Similar data were also reported from Changsha [71] ; time to CR was shorter with an ATRA/ATO combination during induction compared with ATRA alone. Furthermore, patients who received 10 cycles of post-remission combination chemotherapy had a 3-year RFS of 72%, and this was improved to 93% by replacing 4 of the chemotherapy cycles with ATO. & Motivated by a desire to eliminate chemotherapy from the initial management of APL, investigators from the MD Anderson Cancer Center treated 44 patients with ATRA and ATO for induction and consolidation [72] . Nineteen patients with high-risk disease (WCC ≥10×10 9 /L) were also given GO on day 1. CR was achieved in 89% (96% in low-risk, 79% in high-risk); 3 patients with high-risk disease relapsed, whereas no relapses were observed in the 25 patients with low-risk disease. A subsequent report [42• ] from this group included 65 patients treated with the original protocol, and a second cohort of 17 patients where low-risk disease was also treated with GO if the WCC rose above 30×10 9 /L during induction. The 3-year OS was 85%, and DFS 81%. & Whilst ATO manufactured under patent protection is relatively expensive, its low production cost in other locations has encouraged its use as an alternative to ATRA/chemotherapy in induction and consolidation of previously untreated patients. Studies from Vellore [73] and Tehran [74] showed that induction regimens based almost entirely on single agent ATO achieved relatively high CR rates (approximately 86% in both locations); hydroxyurea was used for patients with elevated WCC in both studies, and limited anthracycline was also given to a minority of patients in the Vellore study. Furthermore, ATO monotherapy was also used for consolidation/ maintenance in both studies, although the scheduling was quite different. Mature survival data from both studies [75•, 76 •] have recently been reported. At 5 years, the Vellore results for DFS (80%) and OS (74%) appear superior to those from Tehran (67% and 64%, respectively), and this difference most likely reflects differences in overall duration of ATO exposure. & Whereas most experience with ATO in the initial treatment of APL is derived from single-arm studies, the North American Leukemia Intergroup conducted a randomized study (C9710 [43••] ) to test the hypothesis that the early addition of ATO to post-remission therapy would improve EFS in this setting. After induction with ATRA, daunorubicin and cytarabine, patients in CR received consolidation with ATRA/daunorubicin. Patients randomized to the ATO arm also received 2 cycles of ATO (5 days/week for 5 weeks). Both EFS and DFS were significantly improved in the ATO arm, although this study has been criticized because the control arm performed relatively poorly. For example, 3-year DFS was 90% in the ATO arm and only 70% in the control arm (PG0.0001), whereas another non-ATO protocol that was carried out over a similar time frame (PETHEMA LPA99 [40] ) achieved an 87% 3-year DFS. Nevertheless, the C9710 study demonstrated the multi-center feasibility of delivery, and effectiveness, of ATO in consolidation therapy. Post-remission ATO has also been used as a substitute for a secondcycle of ATRA/chemotherapy consolidation in a single-arm North American study [77] , achieving an 89% 3-year DFS that was comparable with the ATO-arm in C9710. & It is essential to remember that differentiation block at the promyelocyte stage of myelopoiesis, which effectively defines APL, is complicated by 2 intersecting biological phenomena. On the one hand, there is a severe coagulopathy, but strategies that control the coagulopathy by releasing the differentiation block have the potential to cause a lifethreatening DS. Therefore the attraction of an ATRA plus chemotherapy combination, typified by the GIMEMA group's AIDA protocols [36, 39•] , is that ATRA corrects the coagulopathy that is aggravated by idarubicin, and idarubicin protects against ATRA-induced DS. In contrast, despite the theoretical appeal of an ATRA and ATO combination (the 2 most potent agents in APL), their synergism creates a dilemma since both can also cause the APL DS. This is of particular concern for patients with high-risk disease (WCC 910×10 9 /L), who are at greatest risk of hyperleukocytosis which usually accompanies DS. To address this concern, the ALLG incorporated ATRA, ATO, and idarubicin during induction in their APML4 protocol [44••] , aiming to maximize anti-leukemic efficacy whilst simultaneously controlling coagulopathy and DS. Consolidation involved 2 cycles of ATRA and ATO, without any further anthracycline or cytarabine. The results of an interim analysis have been published, and demonstrate excellent results with an early death rate of 3.2%, CR 95%, 2-year freedom from relapse and DFS rates of 97.5%, and 93.2% 2-year OS. These results were compared with a previous non-ATO ALLG protocol (APML3) that used ATRA and idarubicin for both induction and consolidation [78] . APML4 was associated with significantly greater freedom from relapse and failure-free survival. & All patients in the APML4 study were treated identically, regardless of Sanz risk category, and WCC was not an adverse risk factor for early death, relapse (Fig. 1) or OS, suggesting that some anthracycline is beneficial even when an ATRA/ATO combination is used. However, this may only be necessary for patients with high-risk disease, since a randomized study [45••] in patients with low-or intermediate-risk
/L) presented at the 2012 American Society of Hematology meeting showed that ATRA/ATO for induction and consolidation was non-inferior, and possibly superior, to an ATRA/ chemotherapy (AIDA) protocol. Hydroxyurea was used to control the leukocytosis induced by ATRA and ATO in that study. & Table 1 summarizes the regimens and outcome data that have been reported when ATO has been included as part of induction or postremission therapy for previously untreated patients with APL.
ATO toxicity
& The short-term toxicity profile of therapeutic ATO has been well documented in the studies described above, and comprehensively reviewed by investigators from Hong Kong [79] (Table 2 ). In general, toxicity is ameliorated by dose reduction, or by temporary interruption. Active surveillance for QTc prolongation with twice weekly electrocardiographs and strict attention to electrolyte levels (especially K + and Mg 2+ ) is essential to prevent the development of significant and potentially fatal ventricular arrhythmias, at least with intravenous ATO. Scheduling plays an important part in the frequency of ATO side-effects, since the first cycle of consolidation in the APML4 trial, when ATO was administered daily, was associated with considerably more toxicity than the second cycle, when ATO was administered on 5 days/week [44••] . Whereas chronic environmental arsenic exposure is associated with an increased risk of ma-lignancy, second malignancies attributable to therapeutic ATO for APL have not been convincingly demonstrated.
Oral ATO
& Orally administered ATO offers several potential advantages over IV administration, primarily related to logistic issues and lower hospital resource utilization [80] . Oral ATO is associated with lower peak blood levels than after IV administration, but overall arsenic exposure, as estimated by area-under-the-curve, appears comparable [81] . It has been claimed that oral ATO does not cause ventricular arrhythmias because of the lower peak levels, yet a study of oral ATO in relapsed APL found 3 of 16 patients (19%) experienced QTc prolongation beyond 500 msec [82] , whereas a much larger study with IV ATO documented QTc prolongation in 17 of 120 patients (14%) during induction [44••] . The efficacy of oral ATO has primarily been demonstrated in the maintenance setting after first remission [80, 83•] , and for the treatment of relapsed adult [82] and pediatric [84] APL, and its use has been enthusiastically promoted by investigators from Hong Kong, where an oral formulation has been developed and registered for the treatment of APL.
Alternative arsenic formulations
& While the vast majority of publications related to arsenic therapy in APL have involved treatment with ATO, other arsenic derivatives have been examined. Realgar, an ore composed primarily of tetra- /L were included arsenic tetra-sulfide (As 4 S 4 ), also has a long history in traditional Chinese medicine. As 4 S 4 has been shown in a small study to be effective in previously untreated and relapsed APL, and for long term maintenance therapy [85] . It is administered orally, and its toxicity profile is similar to that of ATO. Notably, it can also produce QTc prolongation, and hyperleukocytosis, but usually without other features of DS. Phase III data [86•] currently available in abstract form from the Chinese APL Cooperative Group demonstrate that an oral arsenic-containing Realgar-Indigo naturalis formula and intravenous ATO are associated with comparably high CR rates and long term survival. Other arsenic derivatives whose activity in APL has not yet been well established include liposomal ATO [87] , and several orally bioavailable organic arsenic derivatives (e.g., darinaparsin [88] and melarsoprol [89] ) which appear to have significant antitumor activity. However the likelihood that these agents will be developed for the treatment of APL is remote, as unlike ATO their cytotoxic effects are not mediated by PML-RARA degradation.
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